Search results
13 lis 2017 · It has been suggested that tumor-associated eosinophils in IL-2-treated patients exert cytotoxic effects on cancer cells. 173,187 More recently, cancer immunotherapy with monoclonal antibodies targeting immune checkpoints (CTLA-4, PD-1 and PD-L1) has yielded clinical benefits, including durable responses, to a percentage of patients with ...
31 mar 2024 · Introduction. Eosinophils are end-stage granulocytes derived from myeloid progenitors in the bone marrow in response to stimulation by cytokines, (e.g., interleukin [IL]-3, IL-5, and granulocyte-macrophage colony-stimulating factor [GM-CSF]).
This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a multidisciplinary author panel and accompanied by level of evidence and grade of recommendation, depending on the strength of supporting data and magnitude of benefit from ...
15 maj 2023 · Although early-stage well-differentiated thyroid cancers account for the majority of thyroid cancers on diagnosis and have excellent survival rates, the incidence of advanced-stage disease has increased over the past few years and confers poorer prognosis.
26 maj 2019 · The most common irAEs in any grade were endocrine disorders including thyroid dysfunction and adrenal insufficiency (n = 21) and skin disorders (n = 20). Eosinophilia occurred in 43 cumulative patients (27.7%). Eighteen patients out of them had eosinophilia from baseline.
9 gru 2022 · This review provides a case-based discussion of the differential diagnosis of HES, including the classification by clinical HES subtype. Treatment options are reviewed, including novel eosinophil-targeted agents recently approved for the treatment of HES and/or other eosinophil-associated disorders.
Abstract. Disease Overview: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary or clonal) disorders with potential for end-organ damage. Diagnosis: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 109/L.
